RSH.AX stock closed at A$0.033 on 27 Feb 2026 on the ASX, leaving the healthcare small-cap deeply oversold. Volume finished at 579,396 shares as price settled between A$0.03 and A$0.033. We see a classic oversold bounce setup after a YTD decline of 58.23%. This piece maps the catalysts, risks, and short-term levels for traders seeking a measured rebound in Respiri Limited on the Australian market.

Market snapshot: RSH.AX stock intraday and close

Respiri Limited (RSH.AX) closed at A$0.033 on the ASX. The day’s range was A$0.03 to A$0.033, with market cap at A$51,984,240.00. Volume of 579,396 fell below the 50-day average of 870,341.

Price sits under both the 50-day average A$0.04058 and the 200-day average A$0.05309, a technical sign of extended weakness but potential for a mean-reversion bounce.

Why RSH.AX is oversold: fundamentals and technicals

RSH.AX stock shows heavy short-term declines: YTD -58.23% and 6-month change -58.75%. EPS is -0.01 and reported PE stands at -3.30, reflecting negative earnings. Book value per share is A$0.00259.

Technicals show the share trading well below moving averages. Low liquidity and a small float amplify moves. These factors create an oversold environment suitable for a tactical bounce, but fundamentals remain weak.

Meyka AI grade and analyst consensus

Meyka AI rates RSH.AX with a score out of 100: 67.65 | Grade B | HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects a risky recovery profile with measurable upside potential.

Note: grades are model outputs, not investment advice. Market participants should combine this grade with their own due diligence.

Valuation, financials and key risks

Valuation metrics point to premium ratios versus revenue. Price-to-sales is 113.77, price-to-book is 12.74, and EV/Sales is 114.93. Current ratio equals 1.18 and debt-to-equity is 0.49. Cash per share is A$0.00078.

Key risks include low revenue per share, thin cash reserves, and negative operating cash flow per share -0.00653. These weaken the company’s margin for error during a rebound.

Trading setup: RSH.AX stock oversold bounce strategy

For tactical traders we outline three intraday targets. A conservative rebound target is A$0.06, a base target is A$0.07, and a stretch target is A$0.10. A tactical stop-loss near A$0.025 limits downside on failed bounces.

Use small position sizing due to volatility. Confirm entries with volume above avgVolume 870,341 and short-term RSI or momentum improvements before committing capital.

Sector context and liquidity considerations

Respiri sits in Healthcare, Medical – Devices. The ASX healthcare group has a 3-month performance near -7.95%. Respiri’s price-to-book of 12.74 is above the sector average 3.97, flagging a valuation mismatch. Average sector volume is 2.58M, which exceeds Respiri’s liquidity.

Low liquidity on RSH.AX increases slippage risk. Institutional interest is limited, so monitor block trades and company announcements for catalyst-driven moves.

Final Thoughts

Key takeaways: RSH.AX stock trades at A$0.033 after large declines, creating an oversold bounce opportunity for short-term traders. Meyka AI’s forecast model projects a one-year level near A$0.07, implying an upside of 112.12% versus the current price. This projection reflects mean reversion to prior resistance around A$0.06–A$0.07, and a stretch target of A$0.10 based on the year high of A$0.10. Remember, forecasts are model-based projections and not guarantees. Given negative EPS, thin cash, and high price-to-sales, risk management is essential. We recommend small, disciplined positions, clear stop-losses, and watching for volume confirmation and company updates on the ASX or the company site. For more data-driven views, see the Respiri company site and the ASX company page below for filings and announcements.

Sources: Respiri Limited website and ASX company page for RSH. Meyka AI provides this analysis as an AI-powered market analysis platform

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.